Semaglutide
Symbol Sg · MW 4114 Da
GLP-1 receptor agonist used for glycemic control and weight management.
- Discovered
- 2004
- Half-life
- 7 days
- Approval
- FDA-approved (Ozempic, Wegovy, Rybelsus)
Quick facts
- Category
- Weight Loss
- Route
- Injectable
- Molecular weight
- 4114 Da
- Half-life
- 7 days
- Discovered
- 2004
- Approval status
- FDA-approved (Ozempic, Wegovy, Rybelsus)
Reported effects
- Appetite regulation
- Glucose control
- Significant weight loss
Overview
Semaglutide is a GLP-1 receptor agonist peptide widely known for its role in weight loss, appetite control, and type 2 diabetes management. It works by activating GLP-1 receptors, which help regulate hunger, insulin secretion, blood sugar levels, and stomach emptying. Semaglutide supports weight management by reducing appetite, increasing fullness, and helping lower overall calorie intake. Because of its long half-life, injectable Semaglutide is commonly dosed once weekly, while oral versions are also available for specific medical uses. As one of the most recognized weight loss peptides, Semaglutide has become a major part of modern obesity and metabolic health treatment.
Evidence context
Semaglutide evidence summary
Human clinical evidence
Semaglutide has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
Semaglutide may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for Semaglutide as FDA-approved (Ozempic, Wegovy, Rybelsus). The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable / Oral
- Typical Dosage
- Injectable: 0.25–2.4 mg; oral tablet: 1.5–25 mg depending on indication and titration schedule
- Typical Frequency
- Injectable once weekly; oral once daily
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on Semaglutide.
Internal links
Related peptides
Frequently asked questions
What category is Semaglutide in?
Semaglutide is listed in the Weight Loss category on Peptidic.
What route is Semaglutide associated with?
Semaglutide is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is Semaglutide approved?
Peptidic lists the approval status for Semaglutide as: FDA-approved (Ozempic, Wegovy, Rybelsus). Approval details can vary by indication and jurisdiction.
Interested in Semaglutide?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01